Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025

Multifactorial Disease Models: Their Role in De-risking Topical Formulation Development

A company’s attitude towards risk fundamentally affects their product development strategy, which can vary between the development of a simple or prototype formulation or a fully market-ready, commercially viable product to be used in initial preclinical/clinical evaluation. Large pharma, with many potential drug candidates to prioritise, tends to be more risk-averse and so generally focuses on entering clinical evaluation with a market-ready formulation that has been developed with risk mitigation considered throughout the development process. Dr. Jon Lenn and Prof. Marc Brown at MedPharm explain why, for these large companies, an early failure is much less expensive than a failure in the clinic.

Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025